NanoString Technologies Inc. (NASDAQ:NSTG) Introduces Whole Transcriptome Atlas Through GeoMx Technology Access program

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

NanoString Technologies Inc. (NASDAQ:NSTG) has announced the establishment of a global service network, GeoMx Premier Access Sites, which offers access to GeoMx Cancer Transcriptome Atlas as well as future GeoMx commercial assays.

NanoString introduces new GeoMx Whole Transcriptome Atlas

The company has also announced the availability of a new GeoMx Whole Transcriptome Atlas via the Tech Access Program for the GeoMx Digital Spatial Profiler. These announced initiatives offer expanded access to the latest sequencing readout on GeoMx DSP. Most importantly, the GeoMx Premier Access Site partners will result in a wider user base trying the Cancer Transcriptome Atlas (CTA) and also assess GeoMx DSP applicability in research.

So far, 8 sites have been selected globally, which include the University of Pittsburgh, University of Minnesota, University Medical Centre Utrecht, University of York, Cedar-Sinai Medical Centre, Los Angeles, FynnBio, and Griffith University. Each of these sites will receive advanced training on GeoMx RNA with NGS readout protocol to provide access to CTA and other GeoMX assays in their areas.

Dr. Nic West, Griffith University’s Research Manager, stated that they are delighted to be picked as part of the GeoMx Premier Access Sites. West said that their customers are enthusiastic regarding the incorporation of spatial analysis in research. Cancer Transcriptome Atlas can unlocking novel biology from fresh frozen and formalin-fixed paraffin-embedded tissues, analyzed through bulk sequencing.

GoeMx Whole TranscriptomeAtlasys offers ways of broadening GeoMx RNA profiling

With the expansion of the on the 1800 plus plex CTA, the GeoMx Whole Transcriptome Atlas offers an unbiased view of around 18,000 protein-coding genes. WTA helps in unlocking new pathway that researchers can explore and broadens GeoMX RNA profiling from oncology and immunology to include developmental biology, neuroscience, and other fields.

Chad Brown, the company’s SVP Sales, and Marketing, stated that they are experiencing massive interest from researchers who will like to leverage the potential of next-gen sequencing in studying spatial biology. He added that they are upbeat about the discoveries that can result in the whole transcriptome’s spatial analysis.